Marcio Andrade‐Campos

928 total citations
34 papers, 328 citations indexed

About

Marcio Andrade‐Campos is a scholar working on Genetics, Hematology and Physiology. According to data from OpenAlex, Marcio Andrade‐Campos has authored 34 papers receiving a total of 328 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Genetics, 12 papers in Hematology and 12 papers in Physiology. Recurrent topics in Marcio Andrade‐Campos's work include Lysosomal Storage Disorders Research (12 papers), Lymphoma Diagnosis and Treatment (11 papers) and Chronic Lymphocytic Leukemia Research (10 papers). Marcio Andrade‐Campos is often cited by papers focused on Lysosomal Storage Disorders Research (12 papers), Lymphoma Diagnosis and Treatment (11 papers) and Chronic Lymphocytic Leukemia Research (10 papers). Marcio Andrade‐Campos collaborates with scholars based in Spain, United Kingdom and United States. Marcio Andrade‐Campos's co-authors include Pilar Giraldo, Laura López de Frutos, Beatríz Bellosillo, Amy E. DeZern, David P. Steensma, Peggy Scherle, Rami S. Komrokji, Jeffrey E. Lancet, Alan F. List and Eric Padron and has published in prestigious journals such as Blood, Clinical Cancer Research and British Journal of Haematology.

In The Last Decade

Marcio Andrade‐Campos

33 papers receiving 320 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marcio Andrade‐Campos Spain 11 148 109 77 77 75 34 328
Julien Broséus France 9 136 0.9× 152 1.4× 32 0.4× 32 0.4× 116 1.5× 23 300
Zvenyslava Husak Austria 7 245 1.7× 61 0.6× 88 1.1× 31 0.4× 83 1.1× 8 445
Anna Raimbault France 10 296 2.0× 168 1.5× 34 0.4× 111 1.4× 173 2.3× 17 505
Melania Carlisi Italy 10 105 0.7× 94 0.9× 32 0.4× 39 0.5× 74 1.0× 38 268
Gerlinde Mitterbauer‐Hohendanner Austria 10 327 2.2× 215 2.0× 61 0.8× 32 0.4× 88 1.2× 20 530
Dorthe Rønnov‐Jessen Denmark 9 293 2.0× 159 1.5× 100 1.3× 94 1.2× 75 1.0× 14 465
Shaoyan Hu China 11 128 0.9× 41 0.4× 40 0.5× 15 0.2× 142 1.9× 33 376
M Shtalrid Israel 12 309 2.1× 213 2.0× 66 0.9× 29 0.4× 68 0.9× 28 461
F. M. Fink Austria 11 190 1.3× 60 0.6× 70 0.9× 28 0.4× 125 1.7× 21 439
Hien K. Duong United States 8 261 1.8× 107 1.0× 29 0.4× 18 0.2× 104 1.4× 30 425

Countries citing papers authored by Marcio Andrade‐Campos

Since Specialization
Citations

This map shows the geographic impact of Marcio Andrade‐Campos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marcio Andrade‐Campos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marcio Andrade‐Campos more than expected).

Fields of papers citing papers by Marcio Andrade‐Campos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marcio Andrade‐Campos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marcio Andrade‐Campos. The network helps show where Marcio Andrade‐Campos may publish in the future.

Co-authorship network of co-authors of Marcio Andrade‐Campos

This figure shows the co-authorship network connecting the top 25 collaborators of Marcio Andrade‐Campos. A scholar is included among the top collaborators of Marcio Andrade‐Campos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marcio Andrade‐Campos. Marcio Andrade‐Campos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Desai, Pinkal, Sagar Lonial, Amanda F. Cashen, et al.. (2024). A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies. Clinical Cancer Research. 30(21). 4844–4855. 15 indexed citations
2.
Andrade‐Campos, Marcio, Blanca Sánchez‐González, Concepción Fernández‐Rodríguez, et al.. (2024). Cell-Free DNA as a Biomarker at Diagnosis and Follow-Up in 256 B and T-Cell Lymphomas. Cancers. 16(2). 321–321. 1 indexed citations
3.
Brunner, Andrew M., Yiwen Liu, Jacqueline S. Garcia, et al.. (2024). Clinical Activity and Safety of the Oral ATR Inhibitor Ceralasertib (AZD6738) in Patients with MDS or CMML after Prior HMA Therapy. Blood. 144(Supplement 1). 1833–1833. 1 indexed citations
4.
Roca‐Espiau, Mercedes, et al.. (2023). Advantages of digital technology in the assessment of bone marrow involvement in Gaucher's disease. Frontiers in Medicine. 10. 1098472–1098472. 3 indexed citations
5.
Rodríguez‐Sevilla, Juan José, Luís Colomo, Eva Gimeno, et al.. (2021). Massive intrasplenic arterial thrombosis in a patient with chronic ITP during the development of an Evans syndrome. Thrombosis Research. 208. 226–229. 1 indexed citations
6.
Vázquez, Ivonne, Anna Puiggros, Blanca Sánchez‐González, et al.. (2021). Lack of expression of LMO2 clone SP51 identifies MYC rearrangements in aggressive large B-cell lymphomas. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 479(6). 1073–1078. 2 indexed citations
7.
Cerio, Ascensión López-Dı́az de, Ricardo Garcı́a-Muñoz, Ángel Panizo, et al.. (2020). Maintenance therapy with ex vivo expanded lymphokine‐activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression. British Journal of Haematology. 189(6). 1064–1073. 5 indexed citations
8.
Andrade‐Campos, Marcio, et al.. (2020). Direct and indirect effects of the SARS-CoV-2 pandemic on Gaucher Disease patients in Spain: Time to reconsider home-based therapies?. Blood Cells Molecules and Diseases. 85. 102478–102478. 24 indexed citations
9.
Calvo, Xavier, Lourdes Florensa, Marcio Andrade‐Campos, et al.. (2020). Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features. Blood Advances. 4(20). 5285–5296. 25 indexed citations
10.
Roca‐Espiau, Mercedes, et al.. (2019). Muscle-tendon weakness contributes to chronic fatigue syndrome in Gaucher’s disease. Journal of Orthopaedic Surgery and Research. 14(1). 131–133. 3 indexed citations
11.
Andrade‐Campos, Marcio, et al.. (2018). Gaucher disease and chronic myeloid leukemia: first reported patient receiving enzyme replacement and tyrosine kinase inhibitor therapies simultaneously. Clinical Case Reports. 6(5). 887–892. 3 indexed citations
12.
Andrade‐Campos, Marcio, J L Capablo, Mercedes Roca‐Espiau, et al.. (2018). Twenty-Five Years Diagnosing Gaucher’s Disease in Spain, What We Have Learned?. Blood. 132(Supplement 1). 1110–1110.
13.
Andrade‐Campos, Marcio, Ilda Murillo, Ramón García‐Sánz, & Pilar Giraldo. (2017). Immunoparesis in IgM gammopathies as a useful biomarker to predict disease progression. Clinical Chemistry and Laboratory Medicine (CCLM). 55(10). 1598–1604. 7 indexed citations
14.
Andrade‐Campos, Marcio, et al.. (2017). Assessing underlying chronic inflammation status in type 1 Gaucher disease patients (GD1): involvement of lipocaline (LCN2) and other monocyte cytokines. Molecular Genetics and Metabolism. 120(1-2). S22–S22. 1 indexed citations
15.
Padron, Eric, Amy E. DeZern, Marcio Andrade‐Campos, et al.. (2016). A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML). Clinical Cancer Research. 22(15). 3746–3754. 62 indexed citations
16.
Andrade‐Campos, Marcio, et al.. (2016). The utility of magnetic resonance imaging for bone involvement in Gaucher disease. Assessing more than bone crises. Blood Cells Molecules and Diseases. 68. 126–134. 10 indexed citations
17.
Castro-Orós, Isabel de, Pilar Irún, Pilar Alfonso, et al.. (2015). Experience with 7-ketocholesterol and ccl18/parc as surrogated biomarkers in a series of Spanish Niemann–Pick disease type C patients. Molecular Genetics and Metabolism. 114(2). S29–S29. 5 indexed citations
18.
Andrade‐Campos, Marcio, et al.. (2015). Patients Older Than 65 Years With Non-Hodgkin Lymphoma Are Suitable for Treatment With 90Yttrium-Ibritumumab Tiuxetan: A Single-Institution Experience. Clinical Lymphoma Myeloma & Leukemia. 15(8). 464–471. 6 indexed citations
19.
Irún, Pilar, Marcio Andrade‐Campos, Vanesa Andreu, et al.. (2014). Iron homeostasis and infIammatory biomarker analysis in patients with type 1 Gaucher disease. Blood Cells Molecules and Diseases. 53(4). 171–175. 15 indexed citations
20.
Andrade‐Campos, Marcio, et al.. (2013). Dosing and monitoring of enoxaparin therapy in children. Blood Coagulation & Fibrinolysis. 24(2). 194–198. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julien Broséus Breakdown of academic impact, for papers by Zvenyslava Husak Breakdown of academic impact, for papers by Anna Raimbault Breakdown of academic impact, for papers by Melania Carlisi Breakdown of academic impact, for papers by Gerlinde Mitterbauer‐Hohendanner Breakdown of academic impact, for papers by Dorthe Rønnov‐Jessen Breakdown of academic impact, for papers by Shaoyan Hu Breakdown of academic impact, for papers by M Shtalrid Breakdown of academic impact, for papers by F. M. Fink Breakdown of academic impact, for papers by Hien K. Duong
Rankless by CCL
2026